In summary, the efforts of the TASK3‐WG1A have built upon previous efforts and expanded general pharmacology studies to include dose records, PK/PD, tolerability, and other elements to generally improve rigor and reproducibility in epilepsy research. Here, KCNK9 is linked to epilepsy.